NEW YORK (GenomeWeb News) – Becton Dickinson today reported that its third-quarter revenues increased nearly 2 percent, but were up 5 percent on a currency-neutral basis.
The Franklin Lakes, NJ-based medical devices, diagnostics, and research products firm generated total revenues of $1.98 billion for the quarter ended June 30, compared to $1.95 billion for the third quarter of 2011. It missed analysts' consensus estimate of $2.02 billion.
Sales for its BD Diagnostics segment increased 2 percent to $642.3 million from $631.4 million, but were up 4 percent on a currency-neutral basis. Its BD Biosciences segment posted sales of $268.2 million, down 3 percent from $275.7 million and flat year over year on a currency-neutral basis. The BD Medical segment reported sales of $1.07 billion, up 2 percent from $1.04 billion and up 6 percent on a currency-neutral basis.
BD posted net income of $326.9 million, or $1.59 per share, compared to net income of $343.1 million, or $1.53 per share, for Q3 2011. Excluding income from discontinued operations — the BD Biosciences – Labware unit the firm is in the process of selling to Corning for $730 million — its EPS for the quarter was $1.52. Analysts, on average, had expected $1.53.
BD's R&D spending increased 1 percent to $115 million from $114 million, and its selling and administrative costs were up a fraction of a percent at $469.1 million from $468 million.
The firm said that it full-year revenues are expected to be up 1 percent versus its previously disclosed guidance of 1 to 2 percent. It expects to report EPS from continuing operations of $5.33 to $5.38.